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Type 2 inflammatory responses can be elicited by diverse stimuli, including toxins, venoms, allergens, and
infectious agents, and play critical roles in resistance and tolerance associatedwith infection, wound healing,
tissue repair, and tumor development. Emerging data suggest that in addition to characteristic type 2-asso-
ciated cytokines, the epidermal growth factor (EGF)-like molecule Amphiregulin (AREG) might be a critical
component of type 2-mediated resistance and tolerance. Notably, numerous studies demonstrate that in
addition to the established role of epithelial- and mesenchymal-derived AREG, multiple leukocyte popula-
tions including mast cells, basophils, group 2 innate lymphoid cells (ILC2s), and a subset of tissue-resident
regulatory CD4+ T cells can express AREG. In this review, we discuss recent advances in our understanding
of the AREG-EGF receptor pathway and its involvement in infection and inflammation and propose a model
for the function of this pathway in the context of resistance and tissue tolerance.Introduction
The immune system is composed of a complex network of leu-
kocytes interacting with other physiological systems to protect
the host from pathogen invasion and tumorigenesis. Host pro-
tection can manifest itself in two ways: as resistance, the ability
to eradicate invading pathogens or other foreign stimuli; or as
tolerance, the capacity to decrease pathogen- or tumor-induced
damage without affecting pathogen or tumor burden (Medzhitov
et al., 2012; Schneider and Ayres, 2008). Immune-mediated
resistance is tailored to match the type of invading pathogen, al-
lowing for the production of polarized factors that specifically
target distinct pathogens. For example, protective immunity to
many viruses and bacteria is coordinated by the type 1 or type
17 immune response, which can include increases in inter-
feron-g (IFN-g) and interleukin-17 (IL-17), whereas multicellular
parasites elicit type 2 responses, associated with increases in
IL-4, IL-5, IL-9, and IL-13 (Allen and Wynn, 2011; Gause et al.,
2013; Palm et al., 2012; Pulendran and Artis, 2012). In contrast,
tolerance mechanisms that mitigate damage through control of
harmful inflammation and enhanced tissue repair are more
general, and similar mechanisms of tolerance are utilized in
response to a wide array of pathogens and stimuli. As such,
the pathways involved in tolerance often include components
of the type 2 immune response and can be activated by diverse
stimuli, including toxins, venoms, allergens, and infectious
agents such as helminths, bacteria, and viruses (Allen and
Wynn, 2011; Gause et al., 2013; Palm et al., 2012; Pulendran
and Artis, 2012).
Although a wide array of factors contribute to the host
response to pathogen infection or other foreign antigens, the
epidermal growth factor (EGF)-like molecule, Amphiregulin
(AREG), has recently been shown to play a central role in orches-
trating both host resistance and tolerance mechanisms.216 Immunity 42, February 17, 2015 ª2015 Elsevier Inc.Although AREG and other EGF family members are originally
described as epithelial cell-derived factors, recent data show
that AREG can be expressed by multiple populations of acti-
vated immune cells in a variety of inflammatory conditions. At
the current time, the immune cells described to have AREG-ex-
pressing capacity are primarily associated with type 2 responses
(Table 1 and associated references). Recent studies indicate that
AREG is a pivotal factor that can contribute to host resistance
(Zaiss et al., 2006) but is primarily a key factor that induces toler-
ance by promoting the restoration of tissue integrity following
damage associated with acute or chronic inflammation (Burzyn
et al., 2013; Jamieson et al., 2013; Monticelli et al., 2011). In
this review, we will summarize recent developments regarding
the distribution and regulation of AREG expression in the
steady-state and during inflammation. We will then discuss the
role of AREG in resistance and tolerance to a variety of patho-
gens, in promotion of tissue repair and in the regulation of tumor
progression.
Distribution and Regulation of Amphiregulin Expression
AREG, a member of the epidermal growth factor (EGF) family, is
constitutively expressed by a number of epithelial and mesen-
chymal cell types during development and homeostasis (Bera-
sain and Avila, 2014). In addition to being implicated in a variety
of physiologic processes, including regulation of lung morpho-
genesis (Schuger et al., 1996), keratinocyte proliferation (Cook
et al., 1991), and mammary gland development (Li et al., 1992),
studies demonstrating that wounded keratinocytes rapidly
induce robust AREG expression (Kennedy-Crispin et al., 2012)
have contributed to the hypothesis that epithelial-derived
AREG can act to promote tissue repair and integrity. Importantly,
AREG-gene deficient mice display very few abnormalities under
homeostatic conditions (Luetteke et al., 1999), but resolution of a
Table 1. Innate and Adaptive Immune Cell Populations as Sources of Amphiregulin
Arm of Immune
System Cell Type Species Inflammatory Setting Reference
Innate Basophils Human Allergy Qi et al. (2010)
Mouse Contact hypersensitivity Meulenbroeks et al. (2015)
Eosinophils Human Ex vivo GM-CSF stimulation Matsumoto et al. (2009)
Mast cells Human Ex vivo IgE cross-linking Wang et al. (2005)
Human Ex vivo FcεRI aggregation Okumura et al. (2005)
Mouse Dermatitis, T cell transfer
colitis, cancer
Zaiss et al. (2013)
Neutrophils Human Cystic fibrosis Adib-Conquy et al. (2008)
Group 2 innate lymphoid cells
(ILC2s)
Human Atopic dermatitis Salimi et al. (2013)
Mouse Influenza Monticelli et al. (2011)
Dendritic cells Human & mouse
(in vitro)
ATP stimulation Bles et al. (2010)
Adaptive CD4+ T cells Human Ex vivo TCR stimulations Qi et al. (2012)
Mouse Trichuris muris Zaiss et al. (2006)
Regulatory CD4+ T cells (subset) Mouse Muscle injury Burzyn et al. (2013)
Tumor infiltrating CD8+ T cells Mouse Chemical carcinogenesis Kwong et al. (2010)
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rasain et al., 2005; Meulenbroeks et al., 2015; Perugorria et al.,
2008; Zaiss et al., 2006), supporting the hypothesis that AREG
plays a critical role in restoring tissue integrity following infection
or injury.
As our appreciation for the dialog between tissue-resident im-
mune cells and the epithelial cells they interact with grows, accu-
mulating data suggest that the immune systemmight also play a
critical role in AREG-epidermal growth factor receptor (EGFR)
signaling. For example, in the context of various inflammatory
stimuli, basophils (Qi et al., 2010), eosinophils (Matsumoto
et al., 2009), mast cells (Okumura et al., 2005; Wang et al.,
2005; Zaiss et al., 2013), group 2 innate lymphoid cells (ILC2s)
(Monticelli et al., 2011; Salimi et al., 2013), dendritic cells (DCs)
(Bles et al., 2010), and activated CD4+ T cells (Qi et al., 2012;
Zaiss et al., 2006) have all been shown to express AREG
(Table 1). In addition, AREG expression has also been reported
in neutrophils in the sputum of cystic fibrosis (CF) patients
(Adib-Conquy et al., 2008), in a subset of tumor-infiltrating
CD8+ T cells (Kwong et al., 2010) and in a phenotypically and
functionally distinct subtype of FoxP3-expressing CD4+ regula-
tory T cells (Tregs) that accumulates in injured muscles (Burzyn
et al., 2013) or the inflamed colon of mice (Schiering et al.,
2014). These Treg cell populations have a distinct T cell receptor
(TCR) repertoire, express the IL-33R (Burzyn et al., 2013; Schier-
ing et al., 2014) and are distinguished from other Treg cell popu-
lations in that they express AREG (Burzyn et al., 2013). Although
it is possible that other leukocytes might express AREG in a va-
riety of contexts, the cell types currently described to express
AREG and their pattern of activation suggest that immune-
derived AREG is associated with type 2 immune-mediated resis-
tance and tolerance mechanisms.
Furthermore, multiple immune mediators including prosta-
glandin E2 (Berasain et al., 2005; Qi et al., 2012; Shao et al.,
2003), cAMP (Johansson et al., 2004), insulin-like growth fac-
tor-1 (IGF-1) (Rodland et al., 2008), and transforming growth fac-tor-b (TGF-b) (Bennett et al., 1992; Zhou et al., 2012) can induce
AREG expression, suggesting that AREG production might
be regulated by the activation of multiple cell types during an im-
mune response.
Diverse stimuli have been associated with production of
AREG by leukocytes. For example, IL-33 exposure stimulates
AREG expression in ILC2s (Monticelli et al., 2011; Salimi et al.,
2013), but not in multipotent progenitor type 2 cells
(Saenz et al., 2013). Basophils express high quantities of AREG
following exposure to IL-3. However, human basophils produce
substantially less AREG in response to immunoglobulin E (IgE)-
cross-linking than to IL-3 exposure (Qi et al., 2010), which is
consistent with evidence from mouse models suggesting that
basophils are heterogeneous in their development and effector
functions (Siracusa et al., 2011). In humans, prostaglandin E2
has been shown to be a potent inducer of AREG expression in
a variety of CD4+ T cell subsets (Qi et al., 2012). In murine
T cells, AREG is expressed in a subset of tissue-resident CD4+
Treg cells (Burzyn et al., 2013) and could be induced by TCR
stimulation in T helper 2 (Th2), but not Th1 cells (Zaiss et al.,
2006), suggesting that AREG expression is restricted within
subsets of CD4+ T cells. Consistent with this, although type 2
inflammation can be initiated independently of AREG in some
contexts (Kajiwara et al., 2010; Yagami et al., 2010), there are a
growing number of disease states linking AREG and type 2
inflammation.
Although the findings outlined above demonstrate that im-
mune cells can be induced to express AREG, numerous open
questions remain related to the biology of AREG responses.
For example, further work is needed to determine how hemato-
poietic AREG expression and function is regulated in vivo. In
addition, how the signals that direct AREG expression from
distinct cell types during development differ from those that
induce AREG expression in response to infection, inflammation,
or injury remains poorly understood. Importantly, the distinct
roles of hematopoietic- and non-hematopoietic cell-derivedImmunity 42, February 17, 2015 ª2015 Elsevier Inc. 217
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bound protein, and activation of AREG on non-hematopoietic
cells is regulated largely at the level of release from the cell mem-
brane. However, the ability of hematopoietic cells to migrate
to the site of inflammation and locally upregulate AREG expres-
sion can substantially influence local concentrations of this
growth factor. Thus, hematopoietic and non-hematopoietic cells
might play different roles in contributing to AREG-dependent
responses. Finally, how other pathways regulate AREG respon-
siveness is incompletely defined. For instance, AREG requires
heparin sulfate expression on target cells, which is tightly
controlled during inflammation (Simon Davis and Parish, 2013),
in order to efficiently signal via the EGFR (Johnson and Wong,
1994). These data suggest that a combination of mechanisms
might allow for a highly regulated spatio-temporal accumulation
of AREG at the site of epithelial damage and inflammation.
Further investigation into the regulation of AREG expression,
the significance of hematopoietic- versus non-hematopoietic-
derived AREG and the mechanisms that regulate AREG respon-
siveness will require the development of new genetic tools that
permit the manipulation of AREG expression and responsive-
ness on a cell lineage-specific basis.
Taken together, these studies demonstrate that AREG expres-
sion is elicited by diverse stimuli yet is primarily associated with
immune cell populations activated in type 2 immune responses,
wound repair, and the resolution of inflammation. Below, we will
discuss data that suggest critical roles for hematopoietic-
derived sources of AREG during infection, inflammation, and tis-
sue homeostasis, with particular focus on recent developments
in our understanding of how AREG contributes to the pleiotropic
aspects of type 2 immunity.
Amphiregulin-Mediated Resistance and Tolerance to
Infection
Helminths trigger potent type-2 immune responses in both
mice and humans (Allen and Wynn, 2011; Gause et al., 2013;
Pulendran and Artis, 2012), can cause tissue damage and often
cannot be cleared by the host. The immune system therefore
must develop strategies to tolerate the persisting pathogen
and simultaneously mitigate any associated tissue injury. As
a result, type 2 immunity can not only mediate clearance of path-
ogens but also has additional functions, such as rapid repair of
tissue damage and promoting homeostasis of infected tissues,
which includes the suppression of local inflammation (Allen
and Wynn, 2011; Gause et al., 2013; Pulendran and Artis, 2012).
In the context of helminth infection, where parasite invasion
and the resultant infection-induced inflammatory response can
damage the epithelial layer, enhanced epithelial cell proliferation
has a number of beneficial effects, including repair of damaged
epithelial cells and helminth expulsion via the ‘‘epithelial esca-
lator’’ (Cliffe et al., 2005). Because distinct helminth parasites
utilize various routes to infect the host, a wide range of immune
defense mechanisms have evolved to provide protection while
limiting pathological inflammation (Anthony et al., 2007; Maizels
et al., 2012). For the expulsion of gut-dwelling helminths, the host
immune response induces several different effector mecha-
nisms. In addition to signals that activate the ‘‘epithelial esca-
lator,’’ the type 2 cytokines IL-4, IL-5, IL-9, and IL-13 contribute
to increased muscle contractility, diarrhea, and changes to the218 Immunity 42, February 17, 2015 ª2015 Elsevier Inc.mucus that lines the gastrointestinal tract (Cliffe and Grencis,
2004; Cliffe et al., 2005; Hasnain et al., 2011; Herbert et al.,
2009; Patel et al., 2009). However, the signals that directly regu-
late epithelial cell proliferation during helminth infection remain
less well understood.
AREG is a well-characterized mitogenic stimulus in epithelial
cell layers, making it a potential candidate that could contribute
to epithelial cell responses following helminth infection. Consis-
tent with this, AREG gene-deficient mice exhibit delayed clear-
ance of the intestinal parasite Trichuris muris, which correlated
with diminished proliferation of colonic epithelial cells compared
to infected control mice, suggesting a key role for AREG in pro-
moting tissue-protective epithelial responses in the intestine
(Zaiss et al., 2006). Although the cellular sources of AREG remain
undefined in this setting, enhanced proliferation of the epithelial
cell layer in infected wild-type mice is dependent on CD4+
T cells, further highlighting the importance of the crosstalk be-
tween immune and epithelial cells in the regulation of the
AREG-EGFR pathway.
Recent data have demonstrated important roles for AREG in
the homeostasis of inflamed tissues and epithelial integrity dur-
ing non-helminth lung infections (Monticelli et al., 2011; Turner
et al., 2013). Although type 1 cytokine responses are necessary
for resistance to influenza virus infection, a variety of type 2-
associated cell types populate the lungs following pathogen
clearance to repair and resolve infection-induced tissue damage
and inflammation. For example, following influenza infection of
Rag1/ mice, AREG promotes the regeneration of bronchial
epithelium, which enhances tissue integrity and survival of in-
fected mice (Monticelli et al., 2011). Similarly, in the context of
bacterial-viral co-infections, mice that had been previously in-
fected with influenza rapidly succumb to a consecutive bacterial
infection in the lungs (Jamieson et al., 2013). This effect is not
due to an overwhelming pathogen burden but is instead associ-
ated with impaired tissue integrity and immunopathology. Co-in-
fected mice exhibit increased necrosis in the airway epithelial
cell layer, and genes involved with tissue repair are significantly
downregulated in comparison to single-infected mice. However,
co-infected mice can be rescued by administration of AREG into
the lungs, with no associated influence on pathogen burden.
Finally, fungal infection of Dectin-1 gene deficient mice induces
severe pulmonary pathology compared to wild-type controls
despite similar pathogen burdens, and treatment with recombi-
nant AREG promotes epithelial repair and increased survival of
Dectin-1-deficient hosts (Branzk et al., 2014). These data indi-
cate that AREG is an important growth factor that promotes
host tolerance by sustaining lung tissue integrity and homeosta-
sis following infection-induced tissue damage. The cellular sour-
ces and signaling pathways that regulate AREG induction and its
tissue protective effects outside the context of helminth infection
require further investigation.
Amphiregulin Orchestrates Tissue Repair
and Homeostasis
An important component of type 2 immune responses is the lim-
itation and repair of acute tissue damage (Chen et al., 2012). Hel-
minths migrating through vital organs, such as the lung and liver,
can cause severe, acute tissue damage to the host. In a number
of different settings, type 2 immune responses support tissue
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Figure 1. Amphiregulin Is a Bi-functional Growth Factor that Might
Induce Either Cell Proliferation or Differentiation
The EGFR is a growth-factor receptor well known for its capacity to induce
mitogenic stimuli. Nevertheless, it is also well established that the EGFR is
important for the differentiation of specific cell types. In recent years, it has
been revealed that binding characteristics of EGF ligands and qualitative dif-
ferences in signaling downstream of the receptor dictate the dynamics of gene
expression and the fate of recipient cells. Sustained signals downstream of the
receptor induce stable ERK activation and leads to growth arrest and cell
differentiation, while an oscillating signal downstream of the receptor induces
a repetitive activation and inactivation of ERK, leading to proliferation of the
target cell. AREG is distinct from most other EGF-like growth factors in that it
can not only induce a mitogenic signal but can also induce cell differentiation.
This is explained by a single amino acid difference in the receptor-binding
domain, which decreases the stability of the AREG-EGFR. Such interaction
fails to induce receptor internalization and enables AREG to induce a sustained
signal downstream of the receptor. In contrast, most other EGFR ligands, such
as EGF, TGF-a, or HB-EGF, bind EGFR with high affinity and thereby induce
internalization and degradation of the receptor, and induce negative-feedback
loops within the MAP-kinase signaling cascade. This activation and termina-
tion of an induced signal by the high-affinity ligands of the EGFR in effect lead
to a ligand-specific oscillation of theMAP-kinase signaling pathway and thus a
mitogenic signal in the recipient cell.
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the gut (Seno et al., 2009), and the skin (Lucas et al., 2010).
Helminth-induced type 2 inflammation is characterized by the
activation of a number of innate immune effector cell types,
including ILC2s, alternatively activated (M2) macrophages and
eosinophils. Although these populations have important roles
in pathogen resistance, emerging data suggest that they might
also play important roles in tissue repair. Importantly, tissue
damage itself can provide activation signals for these cell types.
Following cellular stress or tissue damage, adenosine is released
at the site of inflammation, which can induce upregulation of the
alarmin IL-33 and enhance the development of tissue-protective
M2macrophages and eosinophils at the site of parasite infection
(Patel et al., 2014). IL-33 is a potent activator of ILC2s, an innate
source of AREG, and contributes to M2 differentiation. It has
been suggested that M2 macrophages, which can limit acute
inflammation and directly promote tissue repair, can mitigateacute lung injury during worm infections through expression of
Arginase and the epithelial mitogen IGF-1 (Chen et al., 2012).
Notably, the mitogenic activity of IGF-1 is context-dependent
in that IGF-1 alone does not induce epithelial cell proliferation
but can enhance EGFR signaling and proliferative responses in
the presence of EGF family members (Worster et al., 2012).
Furthermore, IGF-1 can induce AREG expression in keratino-
cytes that then contributes to the mitogenic effect of IGF-1
(Rodland et al., 2008; Vardy et al., 1995). Collectively, these
data indicate the possibility that the observed potent mitogenic
stimulus for epithelial cells at the site of infection might be
induced by coordinated expression of AREG and IGF-1. Thus,
immune cells activated by tissue damage and the type 2 immune
response might influence tissue repair and homeostasis through
AREG-dependent pathways. The extent to which this induced
mitogenic stimulus is a direct effect of IGF-1 or in part mediated
by IGF-1 induced AREG in vivo is undefined and warrants further
investigation.
In the context of muscle injury, a similar reparative role of
innate type 2 immune responses and AREG has recently been
shown (Burzyn et al., 2013; Heredia et al., 2013). Upon muscle
injury, eosinophils rapidly infiltrate the wound and eosinophil-
derived IL-4 induces the proliferation of fibro/adipogenic
progenitors (FAPs), thereby preventing their differentiation into
adipocytes. In this way, FAPs supported myogenesis and the
regeneration of skeletal muscle after injury (Heredia et al.,
2013). Further, eosinophil influx is associated with accumulation
of a distinct subpopulation of CD4+ Treg cells at the site of mus-
cle injury (Burzyn et al., 2013). These muscle-resident Treg cells
have a characteristic gene expression pattern and a restricted
TCR repertoire that distinguishes them from circulating Treg
cells. Furthermore, these muscle-resident Treg cells express
AREG, which can enhance the myogenic differentiation of skel-
etal muscle satellite cells in vitro. In vivo, muscle healing could
be enhanced by injection of recombinant AREG into the injured
muscle, while healing was inhibited by Treg cell depletion (Bur-
zyn et al., 2013). These data indicate that innate immune re-
sponses as well as Treg cell-derived AREG play an important
role through various mechanisms in muscle regeneration after
injury.
AREG is well-suited for these diverse roles in tissue repair,
because it is distinct from most other EGF-like growth factors
in that it can not only induce a mitogenic signal but can also
induce cell differentiation. This unexpected activity of a ‘‘growth
factor’’ is the basis for the name ‘‘Amphi’’-regulin, as this factor
induces proliferation in some cell lines, while inducing growth
arrest and differentiation in others (Shoyab et al., 1988). While
EGFR signaling mechanisms have been reviewed comprehen-
sively elsewhere (Arteaga and Engelman, 2014; Avraham and
Yarden, 2011), how AREG might mediate differential effects of
EGFR signaling to promote tissue homeostasis is a key area of
investigation. The demonstration that AREG binds the EGFR
with unusually low affinity (Jones et al., 1999) and displays differ-
ential binding capacity for the EGFR compared to other EGFR li-
gands (Macdonald-Obermann and Pike, 2014) helps to explain
how AREG can mediate distinct biological outcomes compared
to other EFG-likemolecules (Figure 1). Due to a single amino acid
difference in its receptor-binding domain compared to other
EGF-family members, AREG forms an unstable interaction withImmunity 42, February 17, 2015 ª2015 Elsevier Inc. 219
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nalization (Stern et al., 2008), leading to sustained downstream
signaling. This is in contrast to other EGFR ligands, which bind
EGFR with high affinity and thereby induce a rapid internalization
and degradation of the EGFR, and associated negative feedback
loops within the MAP-kinase signaling cascade (Avraham and
Yarden, 2011).
This activation and termination of an induced signal by the
high-affinity ligands of the EGFR in effect leads to a ligand-spe-
cific oscillation of the MAP-kinase signaling pathway (Shankaran
and Wiley, 2010). Such a qualitative difference in signaling
directly dictates the dynamics of gene expression (Purvis and
Lahav, 2013). In fibroblasts, the frequency of the EGFR-induced
oscillation of ERK directly correlates with the strength of the
induced proliferation signal: the higher the ligand concentration,
the higher the pulse frequency and therefore the higher the
induced proliferation (Albeck et al., 2013). However, low-affinity
binding by AREG fails to induce this oscillating signal, and
sustained, stable activation of ERK is not growth-inducing, but
induces growth arrest and cell differentiation (Imayoshi et al.,
2013; Marshall, 1995; Pasic et al., 2011; Traverse et al., 1992).
As a consequence, AREG induces differentiation in a variety of
different cell lines. Neuronal PC12 cells, for instance, are induced
to proliferate in the presence of EGF and to differentiate in the
presence of AREG (Kimura and Schubert, 1992). Notably, kid-
ney-derived MDCK cells (Chung et al., 2005a), mammary epithe-
lial cells (Mukhopadhyay et al., 2013), and myoepithelial cells
(Pasic et al., 2011) follow a similar pattern, suggesting conserva-
tion of this signaling pathway acrossmultiple cell types. Because
AREG can be rapidly expressed at the site of tissue damage
by infiltrating leukocytes, the capacity of AREG to induce differ-
entiation of tissue resident precursor cells, such as satellite cells
in the muscle, might substantially contribute to tissue repair in a
wide range of different organs.
Amphiregulin Contributes to Fibrosis
A critical aspect of wound repair is the deposition of connective
tissue proteins, such as collagen and fibronectin, in and around
an open wound. Several different cell types, including peripheral
blood circulating fibrocytes, contribute to the deposition of
connective tissue proteins into the wound (Suga et al., 2014).
As a result, a layer of differentiated myofibroblasts can quickly
develop at localized sites of injury where they produce collagen
in order to stabilize and contract the wound, allowing for efficient
healing. However, in situations of chronic inflammation, uncon-
trolled wound repair mechanisms, including unrestrained myofi-
broblast differentiation and activation and excessive collagen
deposition, can lead to fibrosis and impaired organ function
(Allen and Wynn, 2011; Gause et al., 2013).
Accumulating evidence suggests that dysregulation of the
dialog between the immune system and EGFR signaling path-
ways can contribute to pathological fibrosis in the context of
chronic inflammation. The immune cell-derived cytokines IL-13
and TGF-b have been demonstrated to potentiate collagen
deposition and fibrosis in the lung, liver, skin, and intestine
(Ask et al., 2008; Chiaramonte et al., 1999; Desmoulie`re et al.,
1993; Hamid et al., 1994; Zhou et al., 2012), and attempts to
therapeutically target these signaling pathways have revealed
TGF-b-dependent and -independent mechanisms of fibrotic220 Immunity 42, February 17, 2015 ª2015 Elsevier Inc.disease (Kaviratne et al., 2004; Lee et al., 2001). For example,
IL-13 normally signals through a heterodimeric receptor
composed of the IL-4Ra and IL-13Ra1 subunits, and attempts
to inhibit IL-13 signaling using a soluble high-affinity IL-13Ra2
fusion protein as a decoy receptor have achieved promising re-
sults in diminishing hepatic and pulmonary fibrosis (Chiaramonte
et al., 2003; Zheng et al., 2008). However, recent studies have
demonstrated that IL-13 signaling through cell-surface-ex-
pressed IL-13Ra2 onmacrophages can stimulate TGF-b expres-
sion to promote myofibroblast differentiation and fibrosis (Brun-
ner et al., 2013; Fichtner-Feigl et al., 2006). Notably, TGF-b can
regulate AREG expression (Bennett et al., 1992), and AREG
has been ascribed a critical role in the development of TGF-
b-induced pulmonary fibrosis (Zhou et al., 2012). Whether IL-
13 signaling can lead directly to AREG induction through TGF-
b remains to be addressed. Collectively, these data indicate
that immune pathways regulate multiple pro-fibrotic mecha-
nisms and provoke the hypothesis that this might be achieved
at least in part through AREG-EGFR-mediated effects on myofi-
broblasts.
Pathological fibrosis canbe considered an unrestrainedwound
healing response and can involve activation of immune cells typi-
cally associated with type 2 immune responses including ILC2
and M2 macrophages. ILC2s have been identified as major
drivers of liver, skin, and pulmonary fibrosis (Chang et al., 2011;
Hams et al., 2014; McHedlidze et al., 2013; Salimi et al., 2013),
and ILC2 express both IL-13 and AREG (Monticelli et al., 2011),
suggesting that ILC2-derived factors might also mediate induc-
tion or progression of inflammation-associated fibrosis. Indeed,
the recent demonstration that a lipidmediator,Maresin1, can limit
ILC2-derived IL-13 andpulmonary inflammation supports this hy-
pothesis (Krishnamoorthy et al., 2014). While ILC2-derived AREG
might substantially contribute to protective tissue remodeling
following influenza-induced damage, its role in fibrosis under
chronic inflammatory conditions remains undefined. Notably,
EGFR inhibitors can ameliorate symptoms of fibrotic disease in
mice (Le Cras et al., 2011; Liu et al., 2012; Vargaftig and Singer,
2003). Identification of the EGFR ligands that support fibrosis,
and defining the role of immune-derived AREG in this process,
remains an area of ongoing investigation that might reveal new
targets for therapeutic intervention.
Amphiregulin and Tregs Can Suppress Local
Inflammation
Successful wound repair requires efficient resolution of local
inflammation (Martin and Leibovich, 2005) as dysregulation of
pathogen-elicited immune responses carries the risk of inducing
collateral tissue damage. Thus, efficient resolution of local
inflammation is necessary to prevent excessive wound-healing
responses and tissue fibrosis. An important cell type associated
with type 2 immune responses that contributes to local immune
suppression is the mast cell (de Vries and Noelle, 2010). Mast--
cell-derived IL-10, for example, has a prominent immune regula-
tory function in a number of different settings (Grimbaldeston
et al., 2007; Leveson-Gower et al., 2013). Furthermore, efficient
induction of immune tolerance can involve collaboration be-
tween mast cells and Treg cells (Lu et al., 2006), potentially
due to the role of mast-cell-derived AREG in supporting Treg
cell function (Zaiss et al., 2013). In the absence of mast-cell-
Figure 2. Amphiregulin Enhances
Regulatory T Cell Function
AREG has been shown to be of critical importance
for efficient CD4+ regulatory T (Treg) cell function,
and in the absence of AREG, CD4+ Treg cells
cannot suppress local inflammation. As CD4+ Treg
cells become activated, they upregulate the
EGFR, in part via STAT5-mediated signaling.
These activated regulatory T cells migrate to the
site of inflammation, where they are exposed to
AREG, which enhances their suppressive capac-
ity, possibly through secretion of immunosup-
pressive exosomes. Depending on the type and
the site of inflammation, CD4+ Treg cells are
dependent on different cell types for AREG; in
chronic inflammation, mast-cell-derived Amphir-
egulin enhances CD4+ Treg cell function, whereas
in an acute inflammatory response, basophils are
described as the main source of AREG. In addi-
tion, some organs contain tissue-specific CD4+
Treg cells. In response to inflammation, these tis-
sue-resident Treg cells can produce Amphiregulin
that might act in an autocrine fashion to enhance
their suppressive capacity. The extent that AREG
derived from these different cell types contributes
to immune regulation within inflamed tissues is an
ongoing area of study.
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litis in a T cell transfer inducedmouse colitis model, are unable to
induce an immunosuppressive environment in a mouse tumor
vaccination model and fail to suppress dermal inflammation
(Zaiss et al., 2013). Furthermore, the development of dermatitis
could be reversed by the co-transfer of bone-marrow-derived
mast cells differentiated from wild-type, but not AREG-deficient
bone marrow (Zaiss et al., 2013). Together, these data demon-
strate that mast cells can be a critical source of AREG and can
promote CD4+ Treg cell-mediated suppression of localized
immune responses (Figure 2).
Recent studies have revealed a potential molecular mecha-
nism through which AREG promotes Treg cell function (Okoye
et al., 2014). Treg cells can secrete exosomes that transfer
immunosuppressive micro-RNAs (miRNAs) from Treg cells to
effector T cells, and AREG enhances the secretion of such exo-
somes (Okoye et al., 2014). The source of AREG that enhances
Treg cell function appears to be dependent on the site and the
type of the immune response. In addition tomast cells, basophils
can also be an important source of AREG. In the context of con-
tact hypersensitivity reactions in the skin, basophil-derived and
not mast cell-derived AREG was essential for enhanced Treg
cell function (Meulenbroeks et al., 2015). Taken together, these
findings reveal a mechanism by which mobilized cells of the
innate immune system use AREG to enhance the suppressive
capacity of Treg cells to dampen local immune responses
and to induce peripheral tolerance. These data also raise the
possibility that the specific tissue microenvironment where
inflammation is localized might determine the source of AREG
and influence its function.
The recent finding that tissue-resident Treg cell populations
express AREG themselves (Burzyn et al., 2013) suggests that
these unique Treg cell populations might possess an autocrine
positive feedback loop. Such a mechanism would release tis-
sue-resident Treg cells from the delay associated with leuko-
cyte-derived AREG that is dependent on the influx of cellsinto the site of tissue damage. The degree to which Treg-cell-
derived AREG directly contributes to wound healing and indi-
rectly contributes to resolution of local inflammation remains
undefined.
Amphiregulin Promotes Immune Suppression in the
Tumor Microenvironment
Immune-mediated tolerance mechanisms such as limitation of
inflammation and tissue repair extend beyond mediating the
host response to pathogens. Tumor antigens also elicit immune
responses that promote tolerance, which can allow tumors to
grow unchecked but can also limit inflammation and collateral
damage to healthy tissues surrounding the tumor microenviron-
ment. For instance, a number of factors have been associated
with the progression of epithelial-associated solid tumors,
including local accumulation of CD4+ Th2 cells, M2 macro-
phages, and expression of IL-13 and TGF-b (Jovanovic et al.,
2014; Palucka and Banchereau, 2012; Palucka et al., 2013).
Epithelial-associated solid tumors also very commonly express
the EGFR and are associated with local expression of EGF
ligands, including AREG (Ciardiello and Tortora, 2008; Herbst
et al., 2001; Shao et al., 2003; Yamada et al., 2008). While
the role of AREG in anti-tumor immunity and tolerance remains
unclear, the wide clinical use of EGFR antagonists for the treat-
ment of a number of metastatic epithelial cancers suggests
that AREG might play a critical role in orchestrating responses
to tumors.
Despite the underlying idea that many epithelial tumors
are dependent on EGFR-mediated signals for their growth,
treatment of cancer patients with EGFR antagonists is associ-
ated with multiple side effects, such as skin rashes, fever, sto-
matitis, and diarrhea (Ciardiello and Tortora, 2008), suggesting
the involvement of off-target effects. Because the EGFR is of
central importance for the homeostasis and integrity of the
skin, inhibition of this pathway might underlie the loss of
dermal barrier function (Lichtenberger et al., 2013; MasciaImmunity 42, February 17, 2015 ª2015 Elsevier Inc. 221
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Figure 3. Leukocyte-Derived Amphiregulin
in Health and Disease
Recent evidence implicates hematopoietic-
derived AREG expression as an important
component of pathogen resistance and tissue
tolerance mechanisms. Type 2-associated im-
mune cells of both the innate and adaptive lineages
have been reported to express AREG.
(A) In the context of helminth infection, CD4+ T cells
and AREG promote epithelial cell turnover to
expedite helminth eradication, although the spe-
cific cellular sources of AREG in this process
remain undefined.
(B) Tissue damage can cause upregulation of the
alarmin IL-33, a strong positive stimulus for ILC2
accumulation and cytokine production that can
support tissue-protective M2 macrophage differ-
entiation. Recent data suggest the possibility that
ILC2, M2 macrophages, AREG, and IGF-1 might
collaborate to promote wound healing at mucosal
barrier surfaces.
(C) Uncontrolled wound-healing responses can
result in pathologic tissue fibrosis. It is possible
that the same cells (ILC2 andM2macrophage) and
the same cytokines (IL-13 and AREG) that promote
tissue repair can become dysregulated in the
presence of chronic inflammation and an altered
cytokine milieu to promote fibrotic responses, including myofibroblast differentiation, proliferation, and ECM deposition.
(D) Epithelial-associated solid tumor microenvironments can have high local concentrations of AREG and tumor infiltrating EGFR+ CD4+ Treg cells. Treatment
with EGFR antagonists or Treg-cell-depleting agents can promote tumor regression. Tissue-resident CD4+ Treg cells can express and respond to AREG,
suggesting the possibility that in addition to growth factor starvation of the tumor, EGFR antagonists might function in part to inhibit local CD4+ Treg cell function,
thereby alleviating immunosuppression and enhancing antitumor immune responses, including the activity and function of tumor specific CD8+ cytotoxic T
lymphocytes (CTLs). Much work remains to define the cellular sources of AREG and the mechanisms regulating its expression in inflamed tissues. Increased
understanding of these pathways could reveal new therapeutic targets for multiple disease states.
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Reviewet al., 2013). However, the severe skin reactions might also be
associated with a general dysregulation of the immune system.
In particular, the skin appears very sensitive to immune dysre-
gulation (Dudda et al., 2008), and Treg cell dysfunction in IPEX
children normally first manifests itself in skin rashes (Halabi-Ta-
wil et al., 2009). Thus, it is possible that EGFR antagonists
could function in part via the suppression of local Treg cell
populations.
The significance of Treg cell function in downregulating
immune defenses against tumors has been demonstrated in
mice (Li et al., 2010). The underlying mechanism of CTLA-4
blocking antibodies in enhancing tumor immune responses in
cancer patients remains controversial, as inhibition of CTLA-4
might both enhance anti-tumor effector T cell function and
impair Treg cell function and thereby limit local immunosuppres-
sion. However, recent studies suggest that CTLA-4 blocking an-
tibodies function mainly via the depletion of Treg cells within the
tumor microenvironment (Simpson et al., 2013). These data
indicate that in cancer patients, sustained Treg cell activity sup-
presses anti-tumor immunity. Thus, an effect on Treg cell func-
tion could also explain some of the inflammatory side effects re-
ported by patients treated with EGFR antagonists. Such a
mechanismmight also explain a number of somewhat enigmatic
clinical observations associated with EGFR antagonist treat-
ment. A striking observation in patients treated with EGFR an-
tagonists is that tumor regression rates did not correlate with
the expression of the targeted molecule (i.e., EGFR) on the
responsive tumor cells (Burtness et al., 2005; Kim et al., 2008).
The EGFR is upregulated in a feedback loop, leading to the
expectation that tumors overexpressing the EGFR would be
particularly vulnerable to EGFR antagonism and growth factor222 Immunity 42, February 17, 2015 ª2015 Elsevier Inc.starvation (Herbst et al., 2001). However, in some cases, even
tumors that fail to express detectable amounts of the EGFR
respond in clinically objective ways to monoclonal antibody
therapy (Chung et al., 2005b). Collectively, these data suggest
that EGFR antagonists might restore the function of anti-tumor
immune responses by interfering with local immunosuppressive
EGFR-responsive Treg cells, although this hypothesis remains
to be formally tested.
Recent experimental data in a murine model support the
hypothesis that EGFR inhibitors can relieve local Treg cell
immunosuppression and activate secondary antitumor immu-
nity following tumor immunization (Zaiss et al., 2013). Immuni-
zation of B16 tumor-bearing mice with DCs loaded with a
peptide derived from the immunogenic tumor antigen TRP2
induces a CD8+ T cell response and tumor rejection in AREG
gene-deficient mice, but not in C57BL/6 wild-type mice. Treat-
ment of tumor-bearing mice with EGFR blocking antibody
following immunization with peptide-pulsed DCs also induces
tumor rejection in wild-type mice. Notably, B16 melanoma
cells do not express the EGFR but are dependent on Treg
cell function for the induction of a tumor-intrinsic immunosup-
pressive environment (Sutmuller et al., 2001). Together, these
data suggest that the absence of AREG-EGFR signaling
enhances immunization-induced tumor specific CD8+ T cells
through relief of Treg cell-mediated suppression (Zaiss et al.,
2013). These experimental findings provoke the hypothesis
that Treg cell function might also be diminished in cancer pa-
tients undergoing EGFR antagonist treatment. Conservation of
this pathway is suggested by the finding that in a murine model
of hepatitis B-virus infection, elevated hepatic AREG expres-
sion is associated with the presence of hyper-suppressive
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ReviewEGFR+ CD4+ Treg cells that could limit antiviral CD8+ T cell
function (Dai et al., 2014). Further research examining the
extent to which EGFR antagonists can inhibit the function of
local CD4+ Treg cell populations could impact therapeutic
treatment of multiple disease states, including chronic viral
infection and cancer.
Concluding Remarks and Future Perspectives
The immune system contributes to homeostasis by promoting
host-protective mechanisms against a variety of harmful
insults ranging from toxins, venoms, and allergens to cancerous
cells and infectious agents. Immune-mediated resistance and
tolerance mechanisms, the latter involving both the control of
harmful inflammation and direct contributions to enhanced
wound healing and tissue repair, are key components of the
host-protective response. It is becoming clear that inmany cases
the same cell populations and even the same specific molecules
can simultaneously contribute to the immune functions that
control resistance and tolerance, as well as development or
progression of fibrosis andcancer. In the context of type 2 inflam-
mation elicited by heterogeneous stimuli, AREG is one such
molecule (Figure 3). The ability of AREG to induce epithelial cell
proliferation and differentiation can promote helminth expulsion
in the context of a polarized type 2 response and enhancewound
healing and tissue repair following infection or injury. The effects
of AREG on Treg cells might also down-modulate harmful
inflammation but at the same time potentiate tumor growth.
The demonstration that immune cells can express AREG and
contribute to tissue homeostasis suggests that this is an impor-
tant component of the crosstalk between immune and epithelial
cells. Continued investigation of the signals that elicit immune-
derived AREG, the mechanisms regulating EGFR-mediated
ligation and signaling and development of new genetic tools to
determine the cellular sources of AREG in vivo will greatly in-
crease our understanding of the role the AREG-EGFR pathway
plays in the context of resistance to infection and in tissue toler-
ance. Addressing these gaps in knowledge has the potential to
inform development of new therapeutic interventions for immu-
nity, chronic inflammation, and cancer.
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